Showing results (1-10 of 1,915) with videos related to
Sort By:
Pageof 192
CNS & Neurological Disorders Drug Targets|December 6, 2014
Inhibition of opioid receptor mediated G-protein activity after chronic administration of kynurenic acid and its derivative without direct binding to opioid receptorsFerenc Zador, Reza Samavati, Eszter Szlavicz, et al.CNS & Neurological Disorders Drug Targets|December 4, 2014
Psychological treatments for cognitive dysfunction in major depressive disorder: current evidence and perspectivesRichard J Porter, Katie Douglas, Jennifer Jordan, et al.CNS & Neurological Disorders Drug Targets|December 4, 2014
Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunctionCelina S Liu, Andre F Carvalho, Roger S McIntyreCNS & Neurological Disorders Drug Targets|December 4, 2014
Structural neuroimaging findings in major depressive disorder throughout aging: a critical systematic review of prospective studiesGilberto S Alves, Andre F Carvalho, Felipe K Sudo, et al.CNS & Neurological Disorders Drug Targets|December 4, 2014
Does non-invasive brain stimulation improve cognition in major depressive disorder? A systematic reviewGabriel Tortella, Priscila M L Selingardi, Marina L Moreno, et al.CNS & Neurological Disorders Drug Targets|December 4, 2014
The neuropsychological hypothesis of antidepressant drug action revisitedNiki Antypa, Raffaella Calati, Alessandro SerrettiCNS & Neurological Disorders Drug Targets|December 4, 2014
Cognitive dysfunction in depression: lessons learned from animal modelsGislaine Z Reus, Helena M Abelaira, Daniela D Leffa, et al.CNS & Neurological Disorders Drug Targets|June 17, 2016
Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment ResponseRodica Balasa, Smaranda Maier, Septimiu Voidazan, et al.CNS & Neurological Disorders Drug Targets|June 17, 2016
Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of EpilepsyArindam Ghosh Mazumder, Yogendra Shantaram Padwad, Damanpreet SinghCNS & Neurological Disorders Drug Targets|August 22, 2015
Nanoparticles: A Neurotoxicological PerspectiveAnuradha Pandey, Vajir Malek, Visakh Prabhakar, et al.Pageof 192